February 2017, Volume 3, Issue 3

This issue features a look at health care under the new administration, coverage from the 2016 ASH Annual Meeting, and more.

Table of Contents

back to top


  • Another Clinical Research Secret Thursday, February 2nd, 2017

    In the December 2016 Editor’s Corner (“So You Say You Want to Be a Clinical Researcher?”), Mikkael A. Sekeres, MD, MS, offered advice for fellows and trainees who have set their hearts on becoming academic hematologists, including finding a good mentor and being a “short order chef” who has projects on the stovetop constantly simmering. […]

  • Microphone Moment Monday, January 23rd, 2017

    Entering Monday’s oral abstract session at the 2016 ASH Annual Meeting, my goals were twofold: to see some great science that may influence how I care for my patients and to support my colleague – a faculty member a couple of years out of fellowship. It wasn’t that long ago (or so I keep telling […]

back to top

Society News

  • February 2017: ASH Program for Future Clinical Researchers, Highlights of ASH, and more Thursday, February 2nd, 2017

    ASH Offers Program for Future Clinical Researchers Deadline for Application Fast Approaching  Hematology fellows and junior faculty interested in a career in clinical research are encouraged to apply for the American Society of Hematology’s (ASH) unique year-long education and mentoring program, the ASH Clinical Research Training Institute (CRTI), which offers a broad education on clinical […]

back to top


  • Affordable Care Act: Exit, Stage Right Thursday, February 2nd, 2017

    The rollback of the Affordable Care Act (ACA) is underway. Within hours of taking the oath of office on January 20, President Donald Trump signed an executive order that undermines enforcement of Former President Barack Obama’s signature legislation. Just a week earlier, the GOP-led Senate and House voted to start the process of repealing the […]

back to top

Training & Education

  • February 2017: Navigating Clinical Trials Thursday, February 2nd, 2017

    A clinical trial is a controlled research study conducted by doctors and medical researchers to improve the care and treatment of people who have hematologic disorders or cancer. Taking part in a clinical trial may be the best treatment choice for some patients. There are trials for patients at every stage of treatment as well […]

  • Should I give CHOP-based therapy to a patient with peripheral T-cell lymphoma NOS? Thursday, February 2nd, 2017

    This month, Eric D. Jacobsen, MD, weighs in on administering CHOP-based therapy to a patient diagnosed with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). You Made the Call! We asked, and you answered – See the reader responses below. Also, check out next month’s clinical dilemma! Clinical Dilemma: I recently saw a 65-year-old veteran with […]

back to top

Clinical News

  • Severe Fatigue Affects Survival and Social Reintegration for Hodgkin Lymphoma Survivors Thursday, February 2nd, 2017

    Approximately 40 percent of patients with Hodgkin lymphoma (HL) experience persistent fatigue, a chronic symptom that can affect patients years after successful treatment. In a large, prospective study published in the Journal of Clinical Oncology, researchers characterized fatigue and its effects on the daily lives of nearly 4,000 patients with HL, finding that baseline severe […]

  • Assessing Lenalidomide Plus Rituximab for Patients With MALT Lymphoma Thursday, February 2nd, 2017

    Patients with advanced mucosa-associated lymphoid tissue (MALT) lymphoma are often treated with chemotherapy-based regimens; however, because of the indolent course of the disease, researchers are investigating immunomodulatory, chemotherapy-free strategies, including the combination of lenalidomide and rituximab. In a Letter to the Editor published in Blood, Barbara Kiesewetter, MD, of the Division of Oncology at the […]

  • Where Does Clofarabine Fit in the Treatment of Patients With Acute Myeloid Leukemia? Thursday, February 2nd, 2017

    Adding clofarabine – a second-generation nucleoside analogue – to a standard induction regimen reduced the risk of relapse for patients with newly diagnosed acute myeloid leukemia (AML), but did not improve survival, compared with induction therapy alone, according to results of an open-label, randomized, phase III study published in Blood. The drug did improve survival […]

  • Long-Term Analysis Identifies Encouraging Trends in Hemophilia A Care Thursday, February 2nd, 2017

    From 1999 to 2010, bleeding events among U.S. patients with hemophilia A have dropped dramatically, coinciding with a marked increase in the use of bleeding prophylaxis, according to an analysis of a long-term surveillance project conducted by the Centers for Disease Control and Prevention (CDC) and the United States Hemophilia Treatment Center Network (USHTCN). The […]

back to top

On Location

  • Does the Addition of ATLG Improve Outcomes After Allogeneic Transplantation? Thursday, February 2nd, 2017

    Previous studies have suggested that adding anti-T lymphocyte globulin (ATLG) to the treatment regimen for patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) could reduce the incidence of acute and chronic graft-versus-host disease (aGVHD; cGVHD), but a randomized, double-blind, phase III trial presented at the 2016 ASH Annual Meeting showed mixed results. After two years of […]

  • Clonal Hematopoiesis Predicts Patients Likely to Develop Therapy-Related Myeloid Neoplasms Sunday, December 4th, 2016

    Screening for clonal hematopoiesis at the time of cancer diagnosis could help identify patients with an increased risk of developing secondary, therapy-related myeloid neoplasms (t-MNs), according to research presented by Koichi Takahashi, MD, and colleagues from the University of Texas MD Anderson Cancer Center in Houston. The researchers also found that t-MNs can occur years […]

back to top